Clinical trials: Epidermis
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and…
- Trial name
- MARIPOSA-2 (NCT04988295)
- Testing
- Lazertinib, Amivantamab, Pemetrexed
- Where
- 249 sites in United States, Argentina and 27 more
- Volunteers
- 776 people
- Sponsor
- Janssen Research & Development, LLC
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06321510
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States.
- Trial name
- NCT01149759
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rockefeller University
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Advanced Solid Tumor
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2…
- Trial name
- NCT06299124
- Testing
- RGT-419B
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Regor Pharmaceuticals Inc.
Pain
A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers
The purpose of this single-blinded study in healthy volunteers is to select a Low-Concentration Capsaicin Topical Liquid (LC-CTL) to serve as a control formulation in the further clinical development of Capsaicin Topical Liquid…
- Trial name
- NCT00912262
- Testing
- Capsaicin Topical Liquid
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NeurogesX
Breast Neoplasms, Breast Cancer
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective…
- Trial name
- NCT00284180
- Testing
- Vinflunine, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Transtibial Amputation
Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1
The goal of this clinical trial is to 1) demonstrate the feasibility of monitoring pressure, temperature, and lactic acid density of sweat inside the prosthetic socket, and 2) verify the relationship between mechanical pressure…
- Trial name
- NCT07216183
- Testing
- Walk, Yuga post, E-SWEAT Sensor
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- North Carolina State University
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Cancer of Head and Neck, Neoplasms, Head and Neck
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
The purpose of this study is to test the preventive effects of a combination of drugs: polyphenon E (PPE) derived from green tea extracts, and erlotinib.
- Trial name
- NCT01116336
- Testing
- Erlotinib, Green Tea Polyphenon E
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Lung Adenocarcinoma
Blood Detection of EGFR Mutation For Iressa Treatment
This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.
- Trial name
- Benefit (NCT02282267)
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Peking University Cancer Hospital & Institute
Early-stage Breast Cancer, HER2-positive Breast Cancer
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint…
- Trial name
- PREDIXIIHER2 (NCT03894007)
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 8 sites in Sweden
- Volunteers
- 6 people
- Sponsor
- Renske Altena
Breast Cancer
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic…
- Trial name
- HERA (NCT00045032)
- Testing
- Herceptin
- Where
- 203 sites in Argentina, Australia and 31 more
- Volunteers
- 5,099 people
- Sponsor
- Hoffmann-La Roche
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in combination with bevacizumab, and second line treatment…
- Trial name
- Stop&Go (NCT01935492)
- Testing
- Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
- Where
- Netherlands
- Volunteers
- 420 people
- Sponsor
- Borstkanker Onderzoek Groep
Breast Cancer
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the…
- Trial name
- NCT00193063
- Testing
- Trastuzumab, Gemcitabine
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.